– USA, TX – CDISC today announced the appointments of at the beginning of the year.
The company also announced that current Board member Dr. Erik Pulkstenis now leads the Board as Chair.
“We enthusiastically welcome these new board member. Their strategic leadership, coupled with decades of experience, will be invaluable as we interact with the talented and engaged CDISC executive leadership driving this important and impactful organization forwards,” said Board Chair, Erik Pulkstenis.
David Evans, President, and CEO said, “It’s a pivotal time at CDISC as we evolve organizationally to embrace governance of clinical research information standards. I am delighted to welcome these seasoned leaders who join an active and engaged Board that will deftly guide CDISC on the next stage of our journey.”
About Jonathan Chainey
Jonathan Chainey is an Executive Director and Global Head, Data Standards & Governance within Data Sciences, Product Development at Roche. He leads a global team accountable for the cross-functional governance and adoption of Roche’s CDISC-aligned global data standards across all Roche-sponsored early and late-phase clinical trials.
Before his election to the CDISC Board of Directors, Jonathan served as chair of the CDISC Advisory Council.
About Rhona O’Donnell
Rhona O’Donnell is currently VP, of Data Management Systems and Standards at Novo Nordisk, overseeing clinical data standards, clinical data systems, and data transformation across the Novo Nordisk value chain. Her experience spans global data management project delivery, EDC/clinical database and data transformation strategy and management, delivery model design, departmental financial and commercial management, clinical risk management, technical system selection, and implementation as well as extensive experience in change control and process improvement projects.
About Dominic Labriola
Dominic Labriola is the Chief Data and Analytics Officer of Madrigal Pharmaceuticals. Dr. Labriola has over 35 years experience as a drug developer, overseeing and contributing to the global registration of 20 medicines in multiple therapeutic and more than 20 years serving in executive leadership roles at Bristol Meyers Squibb. His interactions with global regulatory agencies have given him a unique understanding of the drug approval process and the importance of quality data to support those filings. An expert in trial designs and leveraging innovative approaches, he possesses a particular appreciation for the importance of data standards to support clinical research.
About CDISC
CDISC creates clarity in clinical research by convening a global community to develop and advance data standards of the highest quality. Required by the United States Food and Drug Administration and Japan’s Pharmaceuticals and Medical Devices Agency, recommended by the China National Medical Products Administration, and adopted by the world’s leading research organizations, CDISC standards enable the accessibility, interoperability, and reusability of data. With the help of CDISC standards, the entire research community can maximize the value of data for more efficient and meaningful research that has an invaluable impact on global health. CDISC is a 501(c)(3) global nonprofit charitable organization and is headquartered in Austin, Texas, with hundreds of employees, volunteers, and member organizations around the world.
For more information: https://www.cdisc.org/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
